Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what plans his Department has to provide chemotherapy and immunotherapy concurrently for the treatment of lung cancer through the NHS.

The following chemotherapy and immunotherapy combinations are available for the treatment of lung cancer in England:

- Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (National Institute for Health and Care Excellence (NICE) Technology Appraisal 600) [available via the Cancer Drugs Fund];

- Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NICE Technology Appraisal 577) [available via the Cancer Drugs Fund];

- Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (NICE Technology Appraisal 368); and

- Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (NICE Technology Appraisal 584).

Three other chemotherapy and immunotherapy combinations are currently under review by NICE and NHS England and NHS Improvement await their recommendations.